"High sales growth and strong financial performance in the second quarter"
Summary second quarter 2024
April - June
- Total revenues amounted to
SEK 445 (674) million. Excluding a one-time revenue ofSEK 369 million in Q2 20231, company growth was 46% (41% at CER2) -
Product sales of Buvidal® were
SEK 400 (305) million, an increase of 31% (28% at CER2) and 10% (6% at CER2) compared to previous quarter -
Brixadi® royalties were
SEK 45 (-) million, an increase of 73% (75% at CER2) compared to previous quarter -
Operating result was
SEK 83 (376) million -
Profit before tax was
SEK 104 (381) million. Excluding one-time revenues1, profit before tax increased bySEK 92 million , an increase of 763% -
Cash position at the end of the quarter was
SEK 2,567 (654) million - Data related to treatment efficacy in opioid dependent patients using fentanyl published in JAMA Network Open
- Market Authorization Application (MAA) for CAM2029 for the treatment of acromegaly accepted for review by the EMA
- Phase 3 ACROINNOVA program data presented at ACE 2024, ECE 2024 and ENDO 2024
January - June
- Total revenues amounted to
SEK 835 (958) million. Excluding one-time revenues1, total revenues grew bySEK 246 million , an increase of 42% (40% at CER2) -
Product sales of Buvidal were
SEK 764 (587) million, an increase of 30% (29% at CER2) -
Brixadi royalties were
SEK 71 million - Operating result was
SEK 161 (450) million -
Profit before tax was
SEK 201 (457) million. Excluding one-time revenues1, profit before tax grew bySEK 113 million , an increase of 129% - Company expects to finalize in the mid to high range of 2024 full year guidance
Significant events after the period
- Positive final topline Phase 3 results from ACROINNOVA 2 in patients with acromegaly
Financial summary second quarter 2024
- Total revenues MSEK 445 (674)
- whereof product sales MSEK 400 (305) - OPEX MSEK 331 (270)
- Operating result MSEK 83 (376)
- Result for the period MSEK 74 (301)
-
Profit before tax
SEK 104 (381) million -
Earnings per share, after dilution, of
SEK 1.25 (5.24) - Cash position MSEK 2,567 (654)
1) Excluding a one-time revenue of
2) At constant exchange rates
"
Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at
For more information:
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About
This information is information that
https://news.cision.com/camurus-ab/r/camurus--interim-report-second-quarter-2024,c4015210
https://mb.cision.com/Main/13456/4015210/2916983.pdf
(c) 2024 Cision. All rights reserved., source